Dasatinib monohydrate

Description: Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. Target: Apoptosis, Bcr-Abl, Autophagy, Ephrin Receptor, Src, c-Kit. Smiles: n1cc(sc1Nc1nc(nc(N2CCN(CC2)CCO)c1)C)C(=O)Nc1c(cccc1C)Cl.O. References: O'Hare T, et al. Cancer Res. 2005, 65(11), 4500-4505.